MX2011011676A - Vacuna combinada sarampion-paludismo. - Google Patents

Vacuna combinada sarampion-paludismo.

Info

Publication number
MX2011011676A
MX2011011676A MX2011011676A MX2011011676A MX2011011676A MX 2011011676 A MX2011011676 A MX 2011011676A MX 2011011676 A MX2011011676 A MX 2011011676A MX 2011011676 A MX2011011676 A MX 2011011676A MX 2011011676 A MX2011011676 A MX 2011011676A
Authority
MX
Mexico
Prior art keywords
falciparum
malaria
measles
vaccine
relates
Prior art date
Application number
MX2011011676A
Other languages
English (en)
Inventor
Reinhard Glueck
Agata Fazio
Viviana Gianino
Martin Billeter
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MX2011011676A publication Critical patent/MX2011011676A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0015—Combination vaccines based on measles-mumps-rubella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18442—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una vacuna combinada sarampión-paludismo que contiene diferentes vectores recombinantes de sarampión-paludismo atenuados que comprenden un ácido nucleico heterólogo que codifica para varios antígenos de Plasmodium falciparum. Preferentemente se relaciona con vectores virales que comprenden ácidos nucleicos que codifican la proteína circunesporozoitica de P. falciparum, la proteína 1 de la superficie del merozoíto (MSP-1) de P. falciparum, y sus derivados (p-42; p-83-30-38) en sus formas glucosiladas y secretadas, y el antígeno 1 de la membrana apical (AMA1) de P. falciparum en su forma anclada o secretada. El vector viral se deriva de un virus de sarampión atenuado, basado en una cepa que se usa como vacuna, y es eficiente para transportar el gen de interés que se une y contamina a las células inmunológicas relevantes de manera eficaz. En una modalidad preferida, las proteínas CS, MSP-1 y AMA1 se generan a partir del virus de tal forma que originarán una respuesta inmunológica potente en mamíferos, de preferencia seres humanos; la expresión de proteínas se eleva debido a la optimización del codón humano. Además, la invención se relaciona con el uso de la vacuna recombinante en el tratamiento profiláctico del paludismo.
MX2011011676A 2009-05-05 2010-05-03 Vacuna combinada sarampion-paludismo. MX2011011676A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1181MU2009 2009-05-05
PCT/IN2010/000287 WO2010128524A2 (en) 2009-05-05 2010-05-03 Combined measles-malaria vaccine

Publications (1)

Publication Number Publication Date
MX2011011676A true MX2011011676A (es) 2012-04-02

Family

ID=54259013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011676A MX2011011676A (es) 2009-05-05 2010-05-03 Vacuna combinada sarampion-paludismo.

Country Status (17)

Country Link
US (2) US9119815B2 (es)
EP (2) EP2818175B1 (es)
JP (2) JP2012526102A (es)
KR (3) KR20140070659A (es)
CN (2) CN105617375A (es)
AU (1) AU2010245645A1 (es)
BR (1) BRPI1007584A2 (es)
CA (1) CA2760787C (es)
EA (1) EA026916B1 (es)
HK (2) HK1169039A1 (es)
IL (1) IL216102A (es)
MX (1) MX2011011676A (es)
MY (1) MY175250A (es)
NZ (1) NZ596223A (es)
SG (2) SG175846A1 (es)
UA (1) UA104180C2 (es)
WO (1) WO2010128524A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1375670T3 (da) 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
DK1375512T3 (da) * 2002-06-20 2009-10-26 Pasteur Institut Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CN103965335A (zh) * 2013-01-29 2014-08-06 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
EP2873728A1 (en) * 2013-11-18 2015-05-20 Institut Pasteur A subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides
WO2019224607A1 (en) * 2018-05-23 2019-11-28 Institut Pasteur Recombinant measles virus expressing proteins of a plasmodium parasite and their applications

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86100979A (zh) 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5766597A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
US5756101A (en) 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
EP0575544A4 (en) * 1991-03-20 1997-05-21 Virogenetics Corp Malaria recombinant poxvirus vaccine
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6942866B2 (en) * 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
DE10249390A1 (de) 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
US20050208078A1 (en) * 2003-11-20 2005-09-22 Hoffman Stephen L Methods for the prevention of malaria
CA2507915C (en) 2002-12-17 2013-07-02 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CA2597921A1 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
AU2008288508B2 (en) * 2007-08-13 2014-05-01 Glaxosmithkline Biologicals S.A. Vaccines
EP2280728B1 (en) 2008-05-26 2016-03-02 Cadila Healthcare Limited Combined measles-human papilloma vaccine
JP2010099041A (ja) 2008-10-27 2010-05-06 Arigen Pharmaceuticals Inc 麻疹及びマラリア感染症に対する２価ワクチンとして有用な組換え体麻疹ウイルス

Also Published As

Publication number Publication date
CN102458427B (zh) 2016-02-03
CA2760787A1 (en) 2010-11-11
JP2014231517A (ja) 2014-12-11
EP2427201A2 (en) 2012-03-14
WO2010128524A3 (en) 2011-03-24
US9308250B2 (en) 2016-04-12
EP2818175B1 (en) 2018-11-21
US9119815B2 (en) 2015-09-01
CA2760787C (en) 2017-06-06
KR20150065945A (ko) 2015-06-15
SG175846A1 (en) 2011-12-29
BRPI1007584A2 (pt) 2016-12-06
KR20120014918A (ko) 2012-02-20
WO2010128524A2 (en) 2010-11-11
CN105617375A (zh) 2016-06-01
US20120121538A1 (en) 2012-05-17
HK1169039A1 (zh) 2013-01-18
US20150071876A1 (en) 2015-03-12
KR101616572B1 (ko) 2016-05-11
KR20140070659A (ko) 2014-06-10
IL216102A0 (en) 2012-01-31
NZ596223A (en) 2014-04-30
JP2012526102A (ja) 2012-10-25
AU2010245645A1 (en) 2011-12-08
UA104180C2 (uk) 2014-01-10
CN102458427A (zh) 2012-05-16
EA201171347A1 (ru) 2012-05-30
SG10201402048UA (en) 2014-08-28
IL216102A (en) 2016-05-31
EP2818175A1 (en) 2014-12-31
EA026916B1 (ru) 2017-05-31
MY175250A (en) 2020-06-17
WO2010128524A8 (en) 2011-11-24
HK1221635A1 (zh) 2017-06-09
EP2427201B1 (en) 2015-01-28

Similar Documents

Publication Publication Date Title
Jones et al. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice
MX2011011676A (es) Vacuna combinada sarampion-paludismo.
WO2011138251A8 (en) Lentiviral vector based immunological compounds against malaria
Li et al. Viral vectors for malaria vaccine development
IL214460A0 (en) Malaria prime/boost vaccines
JP2016146837A5 (es)
Noe et al. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate
WO2010079505A3 (en) Combined measles-human papilloma vaccine
EP2477650A1 (en) Virus like particles comprising target proteins fused to plant viral coat proteins
Mendes et al. MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8+ T lymphocytes
Cielens et al. Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein
Ma et al. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen—the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1
US11944674B2 (en) Vaccines
WO2008086386A3 (en) Adenoviral vector-based malaria vaccines
MX354752B (es) Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
Andersson et al. Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen
Mehrizi et al. Immune responses elicited by co‐immunization of Plasmodium vivax and P. falciparum MSP‐1 using prime‐boost immunization strategies
JP2013512866A5 (es)
Yazdanian et al. Evaluation of cellular responses for a chimeric HBsAg-HCV core DNA vaccine in BALB/c mice
Reguzova et al. A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge
Kulkarni et al. Design and characterization of polytope construct with multiple B and TH epitopes of Japanese encephalitis virus
Reeder et al. Strategic variants of CSP delivered as SynDNA vaccines demonstrate heterogeneity of immunogenicity and protection from Plasmodium infection in a murine model
Shen et al. Analysis of the immune response of a new malaria vaccine based on the modification of cryptic epitopes
Lee et al. Trials for the co-expression of the merozoite surface protein-1 and circumsporozoite protein genes of Plasmodium vivax
AU2014201356B9 (en) Combined measles-malaria vaccine

Legal Events

Date Code Title Description
FG Grant or registration